Episode Summary
In Episode 31 of Think Like a Pancreas-The Podcast, host Gary Scheiner and guest Ginger Vieira discuss the innovative approaches being taken by Diamyd Medical in the quest for a cure for type 1 diabetes.
They explore the significance of using precision medicine, and the role of GAD65 therapy to modulate the immune response in the early stages of type one diabetes.
Gary and Ginger share the potential of benefits of Diamyd Medical’s Diagnode-3’s clinical trial, the screening process for participants, and the hope it brings to newly diagnosed individuals.
Key Topics Discussed
- Recent Vertex results
- The autoimmune process
- The importance of precision medicine in treating type 1 diabetes.
- How GAD65 therapy targets specific antibodies without widespread immune suppression.
- The process and benefits of participating in clinical trials
- What is different about Diamyd's Diagnode-3 trial.
- Who qualifies for the Diagnode-3 trial?
- What is involved in being a part of Diamyd's clinical trial?
-
How are outcomes measured?
-
What is in it for participants?
Chapters
- 00:14 – Welcome and Disclaimer
- 01:00 - Introducing Ginger Vieira
- 03:09 – Why Ginger is talking about Diamyd
- 04:00 – Lessons to be learned from Veretex
- 06:11 - How do you define a cure for type 1 diabetes?
- 07:33- What is unique about Diamyd's therapy?
- 08:45 - What is unique about Diamyd's therapy?
- 11:27 – The importance of pre-diabetes screening
- 17:19 - The problem of widespread immunosuppression
- 20:45 - Why should you participate in the Diagnode-3 Clinical Trial?
- 25:36 - How does Diamyd's clinical trial differ from other trials?
- 26:56 - Final Thoughts and Future Directions
- 31:41 - Gary's thoughts on Diamyd Medical's clinical trial
Links:
Version: 20241125
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.